Mar. 20 at 11:19 AM
$SLDB $SRPT
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
Guggenheim analyst Debjit Chattopadhyay initiated coverage of Solid Biosciences (SLDB) with a Buy rating and
$26 price target. Data to-date from its late-stage DMD gene therapy STG-003 appears to have addressed safety issues plaguing Sarepta's (SRPT) Elevidys, says the firm, which anticipates a path towards accelerated approval for -003 as it views leadership changes at the CBER to be beneficial to Solid.
